More specifically, it was assessed if CYP2C8*2 and CYP2C8*3 carriers were at increased risk of new and/or recrudescent infections during the 42-day follow-up period, and if CYP2C8*2 and CYP2C8*3 carriers were at increased risk of experiencing adverse events after AS–AQ treatment. This evidence concerns the gene CYP2C8 and infection.